Role of voriconazole in critically ill patients with invasive mycoses;El papel de voriconazol en pacientes críticos con micosis invasoras

Revista Iberoamericana de Micologia

Volumn 24, Issue 3, 2007, Pages 209-212

  Lerma, Francisco Álvarez ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Critical ill patients; ICU; Invasive mycoses; Voriconazole

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

APACHE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA ALBICANS; CANDIDEMIA; CANDIDIASIS; CRITICALLY ILL PATIENT; DRUG CONTRAINDICATION; DRUG USE; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; INTENSIVE CARE PSYCHOSIS; KIDNEY FUNCTION; LIVER FUNCTION; MYCOSIS; NEUTROPENIA; OBSERVATIONAL STUDY; PREVALENCE; RESPIRATORY FAILURE; REVIEW; SPAIN; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ASPERGILLUS; CANDIDA ALBICANS;

EID: 35348958453     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1130-1406(07)70044-x     Document Type: Review

References (21)

1. Ally R, Schürmenn D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont. B, Hodges M, Troke P, Romero AJ and the Esophageal Candidiasis Study Group. A randomized, double-blind, doble dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-1454.
2. Alvarez-Lerma F, Palomar M, León C, Olechea P, Cerdá E, Bermejo B y Grupo de estudio de infección fúngica. Colonización y/o infección por hongos en Unidades de Cuidados Intensivos. (EPIFUCI). Med Clin (Barc) 2003; 121: 161-166.
3. Álvarez-Lerma F, Nicolás-Arfelis JM, Rodríguez- Borregán JC, Díaz-Regañón J, Sa-Borges M, García-López F, Allepuz-Palau A. Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients. J Chemother 2005; 17: 417-427.
4. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002: 34: 563-571.
5. Díaz Pedroche C, Cisneros JM, Lumbreras C, Aguado JM y Grupo Clínico Español de Estudio de Voriconazol. Tratamiento con voriconazol de las infecciones fúngicas invasoras. Evaluación de la experiencia del uso compasivo de voriconazol en España. Rev Esp Quimioter 2005; 18: 149-158.
6. Ficha téenica de Voriconazol.
7. Garnacho Montero J, León Gil C, Almirante Gragera B, Álvarez Lerma F, Cuenca Estrella M, Garcia Rodriguez JA, Grau Cerrato S, Martín Mazuelos E, Mensa Pueyo J, Nolla Salas J, Olaechea P, Ortiz Leyba C, Prieto Prieto J, Rodríguez AH, Sánchez García M. Recomendaciones terapéuticas en el paciente crítico no neutropénico. Conferencia de Consenso. Conclusiones. Med Intensiva 2005; 3 (Supl 1): 43-52.
8. Grupo de Trabajo de Enfermedades Infecciosas. Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias. Estudio nacional de vigilancia de infección nosocomial en UCI. Informe del 2006.
9. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy on invasive aspergillosis. N Engl J Med 2002; 8: 408-415.
10. Jorda R and EPCAN Group Project. An epidemiological study of fungal infections in ICU. A Spanish multicenter study. Intensive Care Med 1999; 25 (Supl. 1): 171 (Abstract 666).
11. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-1442.
12. León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, and EPCAN study Group. A bedside scoring ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730-737.
13. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802.
14. Nguyen MH, Yu CY. Voriconazole against fluconazole-susceptible and resistant Candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. J Antimicrob Chemother 1998; 42: 253-256.
15. Nolla-Salas J, Sitges-Serra A, León-Gil C, Martínez- González J, León-Regidor MA, Ibáñez-Lucía P, Torres-Rodríguez JM. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med 1997; 23: 23-30.
16. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22: 651-655.
17. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, Just-Nübling G, Schlamm HT, Lutsar I, Espinel-Ingroff A, Johnson E. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131.
18. Swinne D, Watelle M, Nolard N, In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates. Rev Iberoam Micol 2005; 22: 24-28.
19. Valles J, León C, Alvarez Lerma F, and Spanish Collaborative Group for Infections in ICUs. Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Clin Infect Dis 1997; 24: 387-395.
20. Von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006; 6: 6. http://www.biomedcentral.com/ 1472-6904/6/6.
21. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Aneissie EJ. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 2000; 30: 236-237.